EHA 2021 | The management of cytokine release syndrome

Name: The management of cytokine release syndrome
Uploaded: 2021-06-08T00:00:00Z
Duration: 55 s
Description: Daniel W. Lee, MD, University of Virginia, Charlottesville, VA, talks on the management of cytokine release syndrome (CRS) as a side effect of chimeric antigen receptor T-cell (CAR-T) therapy, highlighting the role of early intervention with tocilizumab or corticosteroids. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Daniel Lee • 8 Jun 2021

EHA 2021

General Antibodies Tocilizumab

Daniel W. Lee, MD, University of Virginia, Charlottesville, VA, talks on the management of cytokine release syndrome (CRS) as a side effect of chimeric antigen receptor T-cell (CAR-T) therapy, highlighting the role of early intervention with tocilizumab or corticosteroids. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Daniel W. Lee, MD, has participated in a consultancy role for Harpoon Therapeutics; has participated in an external advisory board for Amgen and Juno/Celgene/BMS; has received institutional research funding from Kite Pharma/Gilead; and is the spouse of an employee of Karyopharm Therapeutics.